{
  "ticker": "IMU",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968870",
  "id": "02968870",
  "pages": 6,
  "price_sensitive": true,
  "date": "20250714",
  "time": "0834",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250714/pdf/06lrqtxw4h73d0.pdf",
  "summary": "- **Clinical Trial Results Update**:  \n  - Additional 5 patients dosed, resulting in **2 Complete Responses (CR)** and **3 Partial Responses (PR)**.  \n  - **Overall Response Rate (ORR)**: 75% (6 CR, 3 PR) in Phase 1b trial for relapsed DLBCL.  \n  - **Durability**: First patient cancer-free at **15+ months**, others at 2, 5, and 11+ months.  \n\n- **Regulatory Milestone**:  \n  - **FDA meeting planned for Q4 2025** to discuss pivotal trial design (following Fast Track Designation).  \n\n- **Trial Expansion**:  \n  - Now enrolling **CAR T-na\u00efve patients** for other lymphomas (e.g., PCNSL, CLL/SLL, MZL).  \n\n- **Next Update**: Expected in **coming months**.  \n\n*[No capital markets or trading-specific actions identified; focus on clinical progress.]*",
  "usage": {
    "prompt_tokens": 2759,
    "completion_tokens": 207,
    "total_tokens": 2966,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-13T22:48:36.233202"
}